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Prostate cancer (PC) is the most commonly diagnosed nonskin malignancy and the second most common cause of cancer death
among men in the United States. Epigenetics is the study of heritable changes in gene expression caused by mechanisms other than
changes in the underlying DNA sequences. Two common epigenetic mechanisms, DNA methylation and histone modiﬁcation,
have demonstrated critical roles in prostate cancer growth and metastasis. DNA hypermethylation of cytosine-guanine (CpG)
rich sequence islands within gene promoter regions is widespread during neoplastic transformation of prostate cells, suggesting
that treatment-induced restoration of a “normal” epigenome could be clinically beneﬁcial. Histone modiﬁcation leads to altered
tumor gene function by changing chromosome structure and the level of gene transcription. The reversibility of epigenetic
aberrations and restoration of tumor suppression gene function have made them attractive targets for prostate cancer treatment
with modulators that demethylate DNA and inhibit histone deacetylases.
1.Introduction
Unlike mutations which cause permanent changes in DNA
sequence, epigenetic changes do not alter the coding se-
quence of genes. They induce conformational changes in the
DNA double helix and modify access of transcription factors
to promoter regions upstream of coding sequences [1]. The
epigenome comprises a tissue-speciﬁc proﬁle of DNA meth-
ylation, histone modiﬁcations, nucleosome remodeling, and
RNA-associated silencing. Cancer is a disease driven by
progressive genetic and epigenetic aberrations that manifest
as global alterations in chromatin packaging and by speciﬁc
promoter changes that inﬂuence the transcription of asso-
ciated genes [1, 2]. In the carcinogenesis of prostate can-
cer, somatic epigenetic alterations appear earlier and more
frequently than genetic sequence changes. Multiple genes
functionally silenced by epigenetic alterations have been
identiﬁed, providing new molecular biomarkers of prostate
cancer and new mechanistic clues into prostate cancer
etiology [3]. This paper will focus on the preclinical evidence
implicating the epigenome as a key mediator in prostate car-
cinogenesis and summarize initial clinical trial experiences
with epigenetic targeted agents.
2. Review Criteria
We searched the PubMed database for articles with the
terms “prostate cancer”, “epigenetics”, “hypermethylation”,
“hypomethylation”, “histone acetylation”, “HDAC”, and
“DNMT”. Original full-text articles published in English
were reviewed. The reference lists of identiﬁed articles were
searched for further relevant papers. No limits were set on
the years of publication. To limit the number of references,
throughout this paper, we have cited reviews rather than
original articles when dealing with matters that are well
established or of a more general nature.2 Prostate Cancer
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Figure 1: Epigenetic mechanism of gene expression silencing. (a) In unmethylated DNA (depicted by white hollow circles on left)
transcription factors (TF) are free to bind gene promotor regions. In hypermethylated DNA (depicted in red ﬁlled-in circles on the right) TF
are blocked from binding to gene promotor regions leading to functional silencing of gene expression. (b) Histone deacetylation by methyl-
CpG-binding domain protein (MPD)/histone deacetylase (HDAC) complexes promotes a condensed structure which inhibit normal gene
transcription. (With permission from [4]).
3. DNA Methylation
DNA methylation is an important regulator of gene tran-
scription, and its role in carcinogenesis has been a topic of
considerable interest in the last few years. Hypermethylation
represses transcription of CpG-rich promoter regions of
tumor suppressor genes leading to gene silencing. DNA
methylation is a covalent chemical modiﬁcation, resulting in
the addition of a methyl (-CH3) group at the carbon-5 posi-
tion of the cytosine ring. This reaction is catalyzed by DNA
methyltransferase (DNMT) in the context of the sequence
5 -CG-3  (also called the CpG dinucleotide) [5]. CpGs are
nonrandomly distributed, and around 1% of human DNA
consists of short, CpG-dense sequences termed CpG islands
[6, 7]. In the unmethylated state, chromatin at these CpG
island regions can be molded into active conformations that
can facilitate the loading of RNA polymerases onto gene pro-
moters. However, 60–90% of CpG dinucleotides are methy-
latedintheadultgenome,andthismodiﬁcationresultsinthe
spontaneous deamination of 5-methylcytosine to thymine;
this reaction changes the chromatin structure and poses a
signiﬁcantbarriertotranscription[7](Figure 1(a)).Approx-
imately half of all the genes in humans have CpG islands,
and these are present on both housekeeping genes and
genes with tissue-specic patterns of expression [8]. Promoter
region CpG islands are usually unmethylated in all normal
tissues, regardless of the transcriptional activity of the gene.
The main exceptions include nontranscribed genes on the
inactive X-chromosome and imprinted autosomal genes
where one of the parental alleles may be methylated [9].
Three active DNA methyltransferases have been identi-
ﬁed (DNMT1, DNMT3A,a n dDNMT3B). DNMT1 is prin-
cipally responsible for maintenance of the cell methylation
proﬁle and to less extent de novo methylation of tumor
suppressor genes. The de novo activity of DNMT1 has
been shown to be stimulated by aberrant DNA structures
[10]. DNMT3A and DNMT3B have both maintenance
and de novo methylation activities and are believed to be
responsible for the wave of methylation that occurs during
embryogenesis [2]. Recently, growing evidence has, however,
indicated that the DNA methylation machinery is in fact
more complicated. For example, it has been demonstrated
that DNMTs physically bind to several histone modiﬁers
including histone deacetylases (HDACs) and EZH2. The for-
mation of multicomponent epigenetic regulatory complex
suggests that DNA methylation and histone modiﬁcation
machineries function in a highly cooperative manner in reg-
ulating chromatin structure and gene expression [11].
4. Hypermethylationin ProstateCancer
Prostate cancer cells commonly have promoter hypermethy-
lation as a means of gene repression in the acquisition and
maintenance of the neoplastic phenotype. This modiﬁca-
tion silences many classic tumor-suppressor gene functions
including hormone signaling, DNA repair, cell adhesion,
cell-cycle control, and apoptosis [12–14]. Speciﬁc genes
implicated within each category are summarized in Table 1.
Tumor suppressor genes frequently altered in other human
cancers such as PTEN, RB1,a n dTP53 are not commonly
hypermethylated in PC, although allelic loss and point
mutations are observed in advanced stage cases [15].
4.1. Hormone Signaling. By far the most studied transcrip-
tional activator in prostate cancer is the androgen receptor
(AR). The AR is a nuclear hormone receptor, which is
activated by binding of androgen ligands. The AR is a critical
eﬀector of prostate cancer development and progression.
Since the growth of PC is initially androgen sensitive, meta-
static disease has been traditionally treated by androgenProstate Cancer 3
Table 1: Hypermethylated genes in prostate cancer.
DNA repair gene
GSTP1
MGMT
Tumor-suppressor genes
APC
RARβ
RASSF1
Hormone receptor genes
AR
ESR1,2
Cell adhesion genes
CDH1
CDH13
CD44
Cell-cycle control genes
CCND2
CDKN1B
SFN
Apoptotic genes
GADD45a
PYCARD
RPRM
GLIPR1
deprivation therapy (ADT). Despite an initial disease con-
trol, progression uniformly occurs due to emergence of
castration-resistant PC cells. Recent studies demonstrated
the continued role of the AR in driving PC cell growth even
in the presence of low levels of circulating androgens and
the emergence of a castrate-resistant prostate cancer (CRPC)
phenotype [16–18]. Epigenetic changes including CpG
methylation and histone acetylation play important roles in
the regulation of AR pathway signaling [19]. Hypermethyla-
tion of the AR gene (AR)i sm o r ef r e q u e n ti nC R P Ct i s s u e s
(29%) compared with untreated primary tissues (10%) sug-
gesting that hypermethylation may contribute to the devel-
opment of a castrate-resistant phenotype [19, 20].
In preclinical studies with prostate cancer cells, Gravina
et al. investigated the potential reversibility of castrate resist-
ance in PC cell lines (the AR positive 22RV1 and the AR
negative PC3) with the hypomethylating agent azacitidine in
combination with the antiandrogen bicalutamide [21, 22].
The addition of azacitidine to bicalutamide induced apop-
tosis in both cell lines and was associated with upregulation
of several proapoptotic mediators (e.g., p16, Bax, Bak, and
p21) with corresponding downregulation of antiapoptotic
factors (e.g., Bcl-2 and Bcl-XL). Interestingly, in PC3 cells,
the AR gene (AR) was reexpressed and correlated with
response to combination therapy. However, AR expression
did not correlate with response in the 22RV1 AR positive
cell line suggesting a “necessary but not suﬃcient” need to
express AR for activity of hypomethylating agents in this
model [23]. Another study investigated hypomethylation as
a therapeutic option to counteract resistance to androgen
deprivation in both AR positive (LNCaP-HR and 22RV1-
HR) and negative cell lines (PC-3) [24]. Inhibition of DNA
methylation reversed castrate resistance correlating with
decreased DNMT1-dependent STAT3 activity.
Of note, not only the AR, but also other members of the
steroidhormonereceptorsuperfamilymayplayaroleinnor-
mal prostate function and tumorigenesis. For instance, the
ESR1 and ESR2 genes encoding the estrogen receptors, ERα
and ERβ, are hypermethylated at low frequencies in PC [15].
4.2. DNA Repair Genes. One of the earliest changes in the
pathogenesis of prostate cancer is CpG island hypermethy-
lation at the glutathione S-transferase (GSTP1)g e n e .GSTP1
is involved in the metabolism, detoxication, and elimination
of potentially genotoxic foreign compounds and thus acts to
protect cells from DNA damage and cancer initiation. The
CpG island promoter region spanning GSTP1 gene becomes
methylated in the majority of prostate tumors. The gene is
expressed and unmethylated in all normal tissues [25]. No
mutations or deletions have been reported for GSTP1 gene
in prostate cancer; however the gene is inactivated and both
allelesarecommonlymethylated[26].Promotermethylation
ofGSTP1isabsentinnormalepitheliumandpresentin6.4%
of proliferative inﬂammatory atrophy, in 70% of high-grade
prostatic intraepithelial neoplasia and in 90% of prostate
cancer[27].TheGSTP1geneencodestheπ-classglutathione
S-transferase (GST), an enzyme capable of detoxifying elec-
trophilicandoxidantcarcinogens[28].Theassociatedlossof
π-class GST function likely sensitizes prostatic epithelial cells
to cell and genome damage inﬂicted by dietary carcinogens
and inﬂammatory oxidants, perhaps explaining the well-
documented contribution of diet and lifestyle factor to
prostatic carcinogenesis [16]. GSTP1 methylation appears
todiscriminatebetweenbenignandpremalignant/malignant
prostateandpersiststhroughallstagesofprostatecancer,and
can be detected in circulating tumor cells (CTCs) [29–32].
The DNA repair protein methylguanine DNA methyl-
transferase (MGMT) removes alkyl adducts from the O6
position of guanine. MGMT expression is decreased in some
tumortissuesandincelllines.Lossofexpressionisrarelydue
to deletion, mutation, or rearrangement of the MGMT gene,
but methylation of discrete regions of the CpG islands of
MGMT has been associated with the silencing of the gene in
cell lines [33]. MGMT hypermethylation plays an important
role in development of prostate carcinoma. In one study the
development of prostate carcinoma was correlated with the
methylation pattern of MGMT [34].
4.3.TumorSuppressionGenes. PromotermethylationinAPC
has been identiﬁed as a marker for prostate cancer prognosis.
Patients with methylation in APC had higher prostate cancer
mortality than patients with an unmethylated cancer [35].
The APC complex is known from studies of colorectal cancer
cells to function as a gatekeeper in the cell, preventing the
transcription of gene products that promote cell prolifera-
tion and survival rather than diﬀerentiation and apoptosis
[36]. Hypermethylation of APC implies silencing of this
gatekeeper function, making the cell vulnerable to further4 Prostate Cancer
epigeneticandgeneticchangesand,thus,progressiontoward
invasive cancer.
Retinoic acid receptor beta (RARβ)a n dPDLM4 have
beenshownto functionastumorsuppressorgenesinhuman
prostatecancercellandxenograftmodels.RARβ andPDLM4
promoters are commonly hypermethylated during prostate
cancer progression [37, 38]. Retinoid acid (RA) exerts its
biological aﬀect through two families of nuclear receptors:
RA receptors (RAR α, β, γ) and retinoid X receptors (RXR
α, β, γ), which are ligand-dependent transcription factors of
the steroid/thyroid hormone nuclear receptor superfamily.
RARβ2 is located in chromosomal region 3p24 and has been
shown to harbor a CpG-rich region in its promoter [39],
which is frequently hypermethylated in prostate cancer [14].
Jer´ onimoetal.showedRARβ2hypermethylationin97.5%of
PC, 94.7% of high-grade prostatic intraepithelial neoplasia
(HGPIN), and 23.3% of BPH. Methylation levels were
signiﬁcantly higher in PC compared with HGPIN and BPH
(P<0.00001) [37].The tazarotene-induced gene 1 (TIG1),
also known as RAR-responsive 1 gene, was ﬁrst identiﬁed
as an RA-responsive gene and was shown to be downregu-
lated in prostate cancer. It is proposed that RARβ silencing
by promoter methylation is a crucial event in prostate tumor
progression and that epigenetic changes in the TIG1 pro-
moter, and possibly in the promoters of other retinoid
response genes, are downstream events to RARβ deﬁciency.
Thus, in the case of TIG1, silencing aﬀects cell-cell contacts
and results in increased proliferation and invasiveness of tu-
mor cells [40].
In addition, inactivation of the tumor suppressor gene
RASSF1A has been associated with hypermethylation of
its CpG-island promoter region [14]. Selective promoter
methylation of the RASSF1A promoter, but not of RASSF1C,
is observed in 53% of prostate cancers and is associated with
higher Gleason score and serum PSA [14]. The encoded
RASSF1A protein was found to interact with DNA repair
protein XPA. Furthermore, the RASSF1A protein has also
been shown to counteract stimulation of cell proliferation by
RAS-linked pathways and inhibit the accumulation of cyclin
D1 and thus induce cell cycle arrest [41].
4.4. Cell Adhesion Genes. Invasion and metastasis are ac-
quired properties during prostate cancer progression, and
involve cancer cells losing intercellular contact, becom-
ing motile, and invading surrounding tissues. E-cadherin
(CDH1) is a strong suppressor of invasion. Decreased CDH1
expression has been associated with more extensive metas-
tases and poor overall survival in prostate cancer patients
[42, 43]. The 5  CpG island of CDH1 is densely methylated
in prostate cancer cell lines (DuPro, TSUPr1, and FNC) [44].
Increased hypermethylation of the CDH1 promoter has been
observed in association with ﬁbroblastic cell morphology
characteristic of epithelial-to-mesenchymal transition in
nonprostate malignancies [45]. CD44 encodes for another
integral membrane protein involved in matrix adhesion and
signal transduction. In prostate cancer, CD44 hypermethy-
lation is seen in 78% of patients compared to only 10% of
patientswithoutcancer[46,47].Thus,CD44maybeanother
important mediator of prostate carcinogenesis.
4.5. Cell Cycle and Proapoptotic Genes. The protein encoded
by CCND2 gene belongs to the highly conserved cyclin
family, whose members are characterized by a dramatic peri-
odicity in protein abundance through the cell cycle. Cyclin D
forms a complex with and functions as a regulatory subunit
of CDK4 or CDK6, whose activity is required for cell cycle
transition from G1 to S phase. Hypermethylation of the
CCND2 promoter is signiﬁcantly higher in prostate can-
cers compared to normal prostate tissues (32%, 6% resp.;
P = 0.004), and there are statistically signiﬁcant concor-
dances between methylation of CCND2 and the methylation
of RARβ, GSTP1, CDH13, RASSF1A,a n dAPC genes [48].
High CCND2 methylation levels characterize invasive PC,
correlating with clinicopathologic features of tumor aggres-
siveness [49].
GADD45α (growth arrest and DNA damage inducible
gene 45 a) is a tumor suppressor gene involved in mainte-
nance of genomic stability, DNA repair, and cell-cycle con-
trol. It is thought to modulate DNMT1 activity at sites of
repair of double-stranded DNA repair during homologous
recombination [50]. GADD45α partially mediates docetaxel
cytotoxicity and can cause active hypomethylation of CpG
residues without the need for DNA replication. GADD45α
is itself methylated at 4 CpG sites proximal to the promoter
region in several epithelial cancers including prostate and
breast cancer [23]. Preclinical work in prostate cancer cell
lines has revealed increased methylation of GADD45α in
DU145 and LNCaP and decreased methylation in PC3 that
correlated inversely with gene expression [51]. Enhanced
sensitivity to docetaxel was observed by upregulation of
GADD45α in DU145 cells by recombinant expression of
GADD45α or pretreatment with 5-azacitidine.
TMS1 (Target of Methylation Induced Silencing 1), also
known as ASC (Apoptosis Speck-like protein containing a
CARD), is a proapoptotic gene that has been shown to play
an important role in the progression of many cancers. TMS1
encodes a protein-containing pyrin domain (PYD) in the
N-terminus and a caspase recruitment domain (CARD) in
the C-terminus, both of which are members of the death
domain-fold superfamily. It is believed that TMS1 induces
apoptosis via the caspase-9 pathway 10 [52, 53]. Methylation
of TMS1 is a frequent event in prostate cancer, and loss
of TMS1/ASC gene expression is associated with complete
methylation of the promoter region in LNCaP prostate
cancer cells [54].
5. HypomethylationinProstateCancer
Hypomethylation is a second methylation defect that is ob-
served in a wide variety of malignancies including prostate
cancer [55]. Hypermethylation changes seem to precede hy-
pomethylation changes, which are generally detected in can-
cers of higher stage and histologic grade and occur hetero-
geneously during prostate cancer progression and metastatic
dissemination [56, 57]. Hypomethylation is observed due to
thediminishedmethylationofabundantrepetitivesequences
that are densely methylated in normal cells, such as LINE-
1r e t r o t r a n s p o s o n s[ 58]. Hypomethylation has been hypo-
thesized to contribute to oncogenesis through multipleProstate Cancer 5
mechanisms including: activation of oncogenes such as c-
MYC and H-RAS, activation of latent retrotransposons,
and by contributing to chromosome instability [5]. Recent
studies have demonstrated strong association between MYC
overexpressioninprostatecancertissuesandclinicalprogres-
sion [59]. MYC is required for androgen-dependent growth
and following its ectopic expression can induce androgen-
independent growth in prostate cancer cells [60].
ThePLAU geneishighlyexpressedinmostprostatecanc-
er tissues and invasive prostate cancer cell lines [61, 62]. The
PLAU gene encodes urokinase plasminogen activator, a mul-
tifunctional protein that can promote tumor invasion and
metastasis in several malignancies including prostate cancer
[3].
DNA hypomethylation has been associated with increas-
ed rates of genomic instability. Speciﬁcally, there is a strong
association between alterations on chromosome 8 and ge-
nome-wide hypomethylation. This association suggests that
PLAU hypomethylation and alterations in chromosome 8
may be mechanistically linked to each other in prostate car-
cinoma [63].
5.1. Histone Modiﬁcation. Three key regulators of histone
modiﬁcation are histone deacetylases (HDACs), histone ace-
tyltransferases (HAT), and histone methyltransferases [64,
65]. Together, HDACs and HATs determine the acetylation
status of histones. Histones are no longer considered to be
simple “DNA-packaging” proteins; they are recognized as
being dynamic regulators of gene activity that undergo many
posttranslational chemical modiﬁcations, including acetyla-
tion, methylation, and phosphorylation. The N-terminal
tails of histone proteins, which protrude out of the nucle-
osome, are rich in positively charged amino acids that are
subject to various reversible posttranslational modiﬁcations.
The status of acetylation and methylation of speciﬁc lysine
residues contained within the tails of nucleosomal core
histonesisknowntohaveacrucialroleinregulatingchroma-
t i ns t r u c t u r ea n dg e n ee x p r e s s i o n[ 66]. Histone modiﬁca-
tions, together with DNA methylation, also have a vital role
in organizing nuclear architecture [64], which, in turn, is
involved in regulating transcription and other nuclear pro-
cesses. Alterations of histone modiﬁcation patterns have the
potential to aﬀect the structure and integrity of the genome
and to disrupt normal patterns of gene expression, which
could be causal factors in cancer [66].
Histone acetylation mediated by HATs is correlated with
transcriptional activation, and histone deacetylation medi-
ated by HDACs is linked to gene silencing (Figure 1(b)). By
removalofacetylgroupsfromhistones,HDACscreateanon-
permissive chromatin conformation that prevents the tran-
scriptionofgenesthatencodeproteinsinvolvedintumorige-
nesis. Histone methylation on arginine and lysine can be as-
sociated with either gene activation or suppression depend-
ing on the amino acid position and the number of methy-
lated residues [67, 68]. Polycomb proteins form chromatin-
modifying complexes that implement transcriptional silenc-
ing in higher eukaryotes. Hundreds of genes are silenced by
Polycomb proteins, including dozens of genes that encode
crucial developmental regulators in organisms ranging from
plants to humans. Two main families of complexes, called
Polycomb repressive complex 1 (PRC1) and PRC2, are tar-
g e t e dt or e p r e s s e dr e g i o n s .
5.2. Histone Modiﬁcation in Prostate Cancer. In PC cell lines
methylation of lysine 9 in histone 3 (H3K9) is linked to
repression of AR genes [69], and histone H3K4 methylation
is associated with AR gene activation in CRPC cell lines
and tissues [70]. H3K4 is signiﬁcantly methylated at the
AR enhancer of the protooncogene UBE2C gene in CRPC,
which leads to AR binding and UBE2C gene expression
[70, 71]. Heat shock protein 90 (TRAP1) plays a key role
in androgen-induced and -independent nuclear localization
and activation of AR. Histone deacetylase 6 (HDAC6) regu-
lates AR hypersensitivity and nuclear localization, mainly via
modulating TRAP1 acetylation [72].
Upregulation of two AR coactivators potently increases
cellular androgen sensitivity. Some of the best studied AR
coactivators are members of the family of SRC1 and trans-
criptional intermediary factor 2 (TIF2)[ 73, 74]. The pro-
teins encoded by SRC1 and TIF2 possess histone acetylase
activities, but are also able to recruit other histone acetylases
such as the CREB-binding protein p300 and PCAF [75]. An
analysis of prostate cancer samples from patients, who failed
endocrine therapy, showed that expression of SRC1 and TIF2
was more intense than in those from patients with benign
prostatic hyperplasia or androgen-dependent tumors [73].
Increasing evidence suggests that histone modiﬁcation
plays important role during prostate tumorigenesis. Changes
in global levels of individual histone modiﬁcations are pre-
dictive of the clinical outcome of prostate cancer indepen-
dently of other features such as tumor stage, preoperative
prostate-speciﬁc antigen levels, and capsule invasion [76],
and may help to identify patients with adverse prognosis
and high risk for recurrence [77, 78]. Speciﬁcally, global
methylations of H3K4 and histone H3 lysine 18 acetylation
(H3K18Ac) are independent predictor of recurrence in low-
grade prostate cancer [76, 79].
Polycomb group (PcG) proteins are transcriptional
repressors that inhibit developmental regulators in embry-
onic stem cells and silence tumor suppressor genes in cancer
[80]. Enhancer of zeste homolog 2 (EZH2) is a subunit of
the Polycomb-repressive complex 2 (PRC2), which catalyses
the trimethylation of histone H3 on Lys 27 (H3K27) and
is involved in genes repression. EZH2 is ampliﬁed and
overexpressed in prostate cancer, with moderate increases
in localized tumors, and higher expression in metastatic
prostate cancers. Overexpression of EZH2 has been associ-
ated with the invasion and progression of prostate cancer
[81, 82]. EZH2 is thought to promote tumorigenesis via
epigenetic silencing of a group of tumor suppressor genes,
including ADRB2, CDH1, PSP94,a n dDAB2IP. Overexpres-
sion of EZH2 trimethylates H3K27 and thus inhibits gene
expression, particularly among tumor suppression genes
(Figure 2). DAB2IP is a novel GTPase-activating protein for
modulating the Ras-mediated signal pathway and tumor
necrosis factor- (TNF-) associated apoptosis. The loss of
DAB2IP expression is frequently detected in metastatic
prostate cancer [83]. Epigenetic silencing of DAB2IP is a key6 Prostate Cancer
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Figure 2: (a) The mutation of EZH2 usually turns on gene transcription. (b) Overexpression of EZH2 in cancer trimethylates H3K27 to
inhibit gene expression, especially among tumor suppressor genes. (c) Cyclin-dependent kinase 1/2 phophorylates EZH2 at Th350 which
resultsinderegulatingtumorsuppressorgenesbyincreasingH3K27-trimethylationlevelsatpromotersofEZH2targetedgenes.(d)Proposed
anti-tumor mechanisms of action of CDK1/2 and EZH2/Th350 inhibitors.
mechanism by which the EZH2 activates Ras and NF-κBa n d
triggers metastasis [84, 85].
Through genome-wide location analysis of prostate
cancer cells, Yu et al. identiﬁed SLIT2 as a top target gene
ofEZH2-mediatedH3K27trimethylation.Overexpressionof
SLIT2 inhibits prostate cancer cell proliferation and inva-
sion. The EZH2-containing Polycomb repressive complexes
bound to the SLIT2 promoter inhibiting its expression.
SLIT2wasdownregulatedinamajorityofmetastaticprostate
tumors exhibiting a negative correlation with EZH2. This
repressed expression could be restored by methylation
inhibitors or EZH2-suppressing compounds [86].
Recently, ETS transcription factors have emerged as
important elements in prostate tumorigenesis due to the
ﬁnding of recurrent translocations involving ETS genes, the
most frequent being the TMPRSS2:ERG gene fusion leading
tooverexpressionoffulllengthERG[87].Kunderfrancoetal.
performed a comprehensive analysis of the ETS gene family
in prostatic normal and tumor tissues and established that
the Polycomb group (PcG) protein EZH2 is a direct target of
ERG and ESE3 and a key player in transcriptional silencing
of the prostate-speciﬁc tumor suppressor gene Nkx3.1 [88].
6.Methylation asaDiagnosticand Prognostic
Marker for Prostate Cancer
Recent studies have shown that methylation of selected genes
may be useful as a biomarker for prostate cancer. GSTP1
methylation appears to discriminate between benign and
premalignant/malignant prostate and persists through all
stages of prostate cancer, and can be detected in circulating
tumorcells(CTCs)[29–32].MethylationofRASSF1,GSTP1,
RARβ, and cadherin genes correlates with clinicopatholog-
ical features of poor prognosis [14]. Methylation of APC,
cyclin D2, GPR7, ABHD9, and expressed sequence tag on
chromosome 3 (Ch3-EST) has been shown to be associatedProstate Cancer 7
with Gleason score, pathological stage, and PSA recurrence
[89–91].
7. Histone Modiﬁcation as a Diagnostic and
Prognostic Marker for ProstateCancer
Histone modiﬁcation patterns have similarly been found to
predict risk of prostate cancer recurrence [76]. Overexpres-
sion of HDAC1 and HDAC2 conveys poor prognosis and
has a highly signiﬁcant negative PSA relapse-free survival
[92, 93]. EZH2 is overexpressed in metastatic prostate cancer
and is a marker of aggressive diseases. By stepwise cross-
validation, Yu et al. developed a “Polycomb repression sig-
nature” composed of 14 direct targets of PcG in metastatic
tumors. Prostate cancers in which this gene signature is re-
pressed show poor clinical outcome and are associated with
cancer progression [94]. SLIT2 is downregulated in prostate
cancer by epigenetic mechanisms and represents a potent
prognostic biomarker that merits further evaluation in large
patient cohorts [86].
8. Epigenome-Targeted Therapy
8.1. Hypomethylating Agents in Prostate Cancer. In preclin-
ical studies, the hypomethylating drug, 5-azacitidine (5-
Aza), demonstrated synergistic eﬀects with docetaxel and
cisplatin in AR-positive 22RV1 and in AR-negative PC3
cells [95]. A structurally similar hypomethylating agent, de-
citabine (DAC), also exhibited synergy with cisplatin and
cyclophosphamide in cell lines although the relationship to
DNA hypomethylation as the mechanism was unclear [96].
In a phase II trial of single agent subcutaneous (SC)
5-Aza in 36 chemona¨ ıve patients with progressive metastatic
or nonmetastatic CRPC and PSA doubling times (PSAdt)
≤3 months, Sonpavde et al. demonstrated promising eﬀects
on PSA kinetics [97]. PSAdt was calculated over a period of 4
weeks at baseline and on therapy. A rapid PSAdt was chosen
to enhance the detection of therapy-related changes in PSA
kinetics; additionally, it is typical for metastatic CRPC to
have a rapid PSA doubling time of <3 months. 5-Aza was
administered at 75mg/m2 SC for 5 days every 4 weeks for up
to 12 cycles. One of the biological concepts was to resensitize
the tumor to combination androgen deprivation therapy.
Thus, LHRH agonist and antiandrogen were continued
withoutantiandrogenwithdrawal.Thirty-fourof36enrolled
patients were evaluable (81% with metastatic disease). A
PSAdt of ≥3 months was attained in 19 patients (55.8%).
Overall median PSAdt was signiﬁcantly prolonged compared
to baseline (2.8 versus 1.5 months, P<0.01). Fourteen pa-
tients had some PSA decline during therapy and 1 patient
had a ≥30% decline compared with baseline. The median
clinicalprogression-freesurvivalwas12.4weeks.AphaseI/II
trial of 5-Aza with docetaxel and prednisone in metastatic
CRPC progressing postdocetaxel is currently enrolling pa-
tients at the University of Miami (NCT00503984). The pri-
maryendpointforthephaseIIportionofthetrialisresponse
by PSA or RECIST criteria. Correlatives planned include
pre- and post-treatment methylation of DNA repetitive
elements in peripheral blood mononuclear cells, GADD45α
methylation in serum DNA, and optional prostate biopsy
tissues using bisulﬁte treatment methylation assays [23].
Thus far, the clinical eﬃcacy outcomes of 5-AZA in human
prostate cancer trials have provided a hint of activity, but no
overwhelming results. One possible reason is the instability
of DNA methylation inhibitors in physiological conditions
in that they became undetectable within a short time after
administration [98]. This can lead cancer cells to take ad-
vantage of DNA methylation recovery systems, resulting in
resilencing of DNA hypermethylated genes. Wong et al. pro-
vided strong evidence for DNA methylation recovery and
found that H3K9 trimethylation and H3K27 trimethylation
were closely associated with DNA methylation recovery [11].
In this regard, the eﬃcacy of DNA methylation inhibitors
in cancer treatment could be signiﬁcantly improved if the
DNA methylation recovery system could be suppressed or
minimized.
8.2. HDAC Inhibitors in Prostate Cancer. Histone deacetylase
(HDAC) is recognized as one of the promising targets for
cancer therapy. In preclinical studies, Valproic acid inhib-
its growth of prostate cancer cells in vitro and reduces tumor
xenograft growth in athymic nude mice owing to inhib-
ition of histone acetylation by HDAC1. This agent has mul-
tiple eﬀects, including cell-cycle arrest, increased apoptosis,
decreased angiogenesis, and induction of senescence [2].
Vorinostat suppresses the growth of the LNCaP and PC-3
cell lines. Furthermore, it also shrinks tumors and suppres-
ses their growth in mice transplanted with CWR22 human
prostate tumor cells [99]. Romidepsin inhibits cell prolifer-
ation by arresting cell-cycle transition at the G1 and G2/M
phases [100]. Entinostat arrests the growth of PC-3 and
LNCaP cells in vitro, induces cell death in DU145 cells,
and inhibits the growth of subcutaneous tumor xenografts
of these three cell lines in vivo. Molecular analysis showed
increased histone H3 acetylation and cyclin-dependent
kinase inhibitor 1 (p21) expression in tumor samples from
entinostat-treated patients. In the transgenic adenocarci-
noma of the mouse prostate (TRAMP)m o d e l ,l o n g - t e r m
treatment with Entinostat slowed tumor progression and
greatly reduced cell proliferation [2].
HDAC inhibitors have been noted to have greater anti-
proliferative eﬀects on AR-positive prostate cancer cells than
their AR-negative counterparts and inhibit xenograft growth
in both castration-sensitive- and resistant models [99, 101].
In a study by Liu et al. LBH589 (Panobinostat) reversed
the resistance of androgen-independent (AI) LNCaP cells to
bicalutamide and to apoptosis. Treatment of bicalutamide-
resistant AI cells with LBH589 combined with bicalutamide
synergistically inhibited cell growth and induced a ﬁvefold
higher level of caspase 3/7 activation [102]. Proposed mech-
anisms of HDAC inhibitor clinical activity in prostate cancer
include: preferential targeting of HDAC6 which deacetylates
HSP90 and decreases AR stability, direct suppression of AR
transcription, and sensitization of prostate cancer cells to
DNA-damaging agents by targeting Ku70 acetylation [101,
103–105]. In light of their high potency to inhibit tumor
cell growth in vivo, HDAC inhibitors have entered human
clinical trial development.8 Prostate Cancer
Bradley et al. reported phase II results in 27 metastatic
CRPCpatientswithprogressivediseaseafteronepriorchem-
otherapy regimen utilizing the oral HDAC class 1 and 2
inhibitor vorinostat administered at a continuous dose of
400mg once per day [106]. No PSA declines ≥50% were ob-
served, with best objective response of stable disease seen
in only 2 patients (7%). In addition, therapy was associated
with considerable toxicity with 44% of patients experiencing
grade 3 adverse events. All patients were taken oﬀ of study
prior to 6 months from therapy initiation. A statistically
signiﬁcant association was observed between high posttreat-
ment IL-6 levels and treatment-related toxicity.
Similarly, Molife et al. reported phase II results in 35 pa-
tients with chemo na¨ ıve metastatic CRPC utilizing the intra-
venous HDAC inhibitor romidepsin administered at a dose
of 13mg/m2 iv days 1, 8, 15 on a 4-week cycle [107]. The
primary endpoint of the study was 6-month disease control
rate deﬁned as the percentage of patients at 6 months with
RECIST complete response, partial response, or stable dis-
ease. According to this deﬁnition, a disease control rate
of 5.7% (2 of 35 patients) was observed. Eleven patients
(31%) had a best response of stable disease; however these
were short lived with none meeting the 6-month dura-
tionnecessarytoqualifyforthe6-monthdiseasecontrolend-
point. Two patients demonstrated a PSA decline ≥50% with
an additional 1 patient showing a PSA decline >30%. Eleven
patients (31%) discontinued therapy due to toxicity.
In addition, combination HDAC inhibitor therapy with
oralpanobinostatandfront-linedocetaxelchemotherapyhas
been investigated by Rathkopf et al. in a phase I study in
16 patients with metastatic CRPC [108]. Patients received
either single-agent panobinostat 20mg oral once daily on
days 1, 3, 5, 8, 10, 12 on a 21-day cycle or panobinostat
15mg according to the same schedule in combination with
intravenous docetaxel 75mg/m2 on day 1. Both the single
agent and docetaxel combination regimens were deemed
feasible from a toxicity standpoint. No responses were seen
with oral panobinostat alone. Five of eight patients (63%)
on the panobinostat plus docetaxel arm demonstrated >50%
PSA declines. In 9 of 11 patients, a >2-fold increase in
peripheral blood mononuclear cell histone acetylation was
observed on day 5 of cycle 1. The study was stopped after
16 patients due to a more favorable pharmacokinetic proﬁle
with an intravenous formulation of panobinostat.
It is not clear why outcomes from clinical trials of HDAC
inhibitors in metastatic CRPC have not matched the pro-
mising preclinical activity and scientiﬁc rationale. Given the
high toxicity seen in these trials leading to dose reductions,
it is possible that suboptimal cell inhibitory plasma con-
centrations of the HDAC inhibitors may explain why less
clinical activity was seen than expected. While HDAC inhibi-
tors can lead to activation of several silenced genes, several
studies have shown that about the same number of genes
are upregulated as are downregulated by these epigenetic
modifyingagents[109].Thereforeclariﬁcationofwhichgene
iscriticalforclinicaleﬃcacyrequiresfurtherstudies.Histone
acetylation as a biomarker for predictive treatment outcome
has been questioned and, while useful as a surrogate for
HDAC inhibition, does not appear to reﬂect tumor response.
9. Conclusion
Prostate cancer is a disease driven by progressive genetic
and epigenetic aberrations. DNA methylation and histone
acetylation are intimately linked, so that global hypomethy-
lation might be expected to lead to global alterations in the
level of histone acetylation and vice versa. These rapidly
emerging data strongly indicate that the entire epigenome is
fundamentallydisturbedinprostatecancerdevelopmentand
therefore represents a target for therapeutic development.
Altered DNA methylation, changes in the expression of
chromatin proteins, and posttranslational histone modi-
ﬁcations can be used for prostate cancer detection and
classiﬁcation. The reversible nature of DNA methylation
forms the basis of epigenetic cancer therapy. However, it has
been reported that DNA remethylation and gene resilencing
could occur after removal of demethylation treatment, and
this may signiﬁcantly hamper the therapeutic value of DNA
methylation inhibitors. We need a better understanding
of the pharmacodynamics and biomarkers that predict
response to HDAC inhibitors in prostate cancer. Epigenetic
targeted therapy is in an early stage of development. Both
at the mechanistic level and at the clinical/therapeutic level,
much remains to be learned. Progress in this area of cancer
therapeutics is promising; however, it is also challenging.
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